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ABSTRACT
Objective: The objective of this study was to evaluate the protective effect of Erdosteine on complete freund’s adjuvant (CFA) induced arthritic rats.
Methods: Wistar Albino rats of 100–250 g were divided into five groups (n=6) and administered with 0.1 ml of CFA subcutaneously into the left 
hind paw except the negative control group. The standard group received methotrexate (MTX) 0.075 mg/kg body weight orally. Besides, the test 
groups received Erdosteine orally at a dose 10 mg/kg and 20 mg/kg bodyweight for 12 days. The changes in body weight, paw volume, hematological 
parameters, radiographical, and histological findings were the indicators to evaluate the efficacy of the test product.
Discussion: Significant change in the body weight, paw volume, radiographical, hematological, and histological parameters were observed which 
supports the remarkable reduction of the arthritic development in the standard and test groups compared to the untreated group. However, the test 
group (Erdosteine) with the dose 20 mg/kg shows to be more potent than the test group (Erdosteine) with a dose 10 mg/kg and the standard group 
(MTX) to reduce the arthritic effect.
Results: The test group with 20 mg/kg Erdosteine showed much better outcome than the standard group at significant (p<0.05). Therefore, Erdosteine 
acting as an anti-inflammatory and anti-oxidant is effective at a dose 20 mg/kg in treating the progression of rheumatoid arthritis in rats.
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects 
a large number of people throughout the world [1]. It is characterized 
by angiogenesis and micro-vascular lesions leading to the infiltration 
of a variety of inflammatory cells into the joint causing swelling, 
stiffness, and pain which finally leads to substantial loss of functioning 
and mobility in its advanced stages. The synovial membrane becomes 
highly vascularized, synovial fibroblasts proliferate, and inflammatory 
cells release numerous cytokines and growth factors into the joint [2]. 
The prevalence of RA varies between 0.3% and 1% worldwide and is 
more common in developed countries. In India, the prevalence of RA 
was reported to be 0.75% in the adult population [3]. It is rare in men 
under 30 years and prevalent in the geriatric population. In women, the 
incidence rises progressively from about 25 years of age to a broad peak 
during 45–75 years [4].
It is well established now that free radicals/reactive oxygen species 
play an important role in inflammation [5]. Control of inflammation 
is the key to slow down or prevent disease progression as well 
as manage symptoms of RA. Thus, it is an approach to treat RA by 
combating those reactive oxygen species with a compound having 
potent antioxidant activity along with traditional anti-arthritic 
effect [6]. The treatment is aimed to relieve pain, inflammation, and 
maintain joint function [7].
Methotrexate (MTX) is prescribed as monotherapy or in combination 
with other synthetic disease-modifying anti-rheumatic drugs 
(DMARDs) [8]. Hendawy et al. 2015, reported that MTX is considered 
by many rheumatologists to be the most important and useful DMARDs 
and is often considered as the first line of treatment [9]. It is most 
active in the developing adjuvant model where the opportunity exists 
to dose it for a longer period (15 days). The ED50 doses are generally 
0.06–0.075 mg/kg/day [10] Therefore, in this study MTX was used as 
a standard drug.
IUPAC name - 2-[2-oxo-2-[(2-oxothiolan-3-yl) amino]ethyl]
sulfanylacetic acid
Erdosteine is a thiol derivative of the same class as acetylcysteine [11] 
developed for the treatment of chronic obstructive bronchitis. Erdosteine 
produces an active metabolite (Met 1) which was shown to produce 
antioxidant effects due to the presence of an SH group [12]. Its 
mechanism of action is its ability to inhibit some inflammatory 
mediators and some pro-inflammatory cytokines that are specifically 
involved in oxidative stress [12]. Based on its free radical scavenging 
activity, its protective effects against oxidant-induced tissue damage 
have been demonstrated in various inflammation models [13].
The study rationale is rooted on the fact that the test drug (Erdosteine) 
which produces low incidence of adverse events [14,15] and prevents 
the accumulation of free radicals [16] in the body can be used as a 
potential agent in RA.
METHODS
Drugs and chemicals
Complete Freund’s adjuvant (CFA) and Erdosteine (test drug) were 
obtained from Sigma-Aldrich Chemicals, Mumbai. MTX was purchased 
from Ipca Laboratories Ltd, Mumbai, and used as a standard drug. 
Erdosteine is a white, microcrystalline powder slightly soluble in water, 
ethanol, methanol, and acetone. It is soluble in 20 mg/ml Dimethyl 
sulfoxide (DMSO) and since it is acidic, it is made neutral by adding 
NaHCO3 Fig. 1. All other chemicals and solvents were of the highest 
grade commercially available.
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
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Animals
Thirty adult Wistar albino rats, weighing 100–250 g were obtained 
from the Central Animal House, NSHM College of Pharmaceutical 
Technology, acclimatized for 7 days with a 12-h light/dark cycle. In 
each cage, five animals were housed with free access to commercial 
food pellet and water ad libitum. The protocol and the facility were 
maintained according to the guidelines provided by the Institutional 
Animal Ethical Committee, where all the animals under study were 
housed in an air-conditioned room 23±1°C and 50% humidity with a 
controlled. The animals were acclimatized in clean cage provided with 
husk bedding for 5 weeks before the study. The procedures throughout 
the study were carried out as per the guidelines of the Committee for 
the Purpose of Control and Supervision of Experiments on Animals.
Acute oral toxicity study
An acute oral toxicity study was carried out using female Wistar 
rats according to the Organization for Economic Co-operation and 
Development guidelines 423. A total of 6 female rats were used, 3 for the 
control group (Group A) and 3 for the test group (Group B). Drug was 
administered orally to overnight fasted rat sat a volume of 1 ml/100 g 
body weight. Erdosteine was dissolved in DMSO and was administered 
at a single dose of 2000 mg/kg [17] in Group B and tap water was 
administered to (Fig. 2) Group A and food was withheld for another 3 h. 
They were observed continuously for 4 h for behavioral and autonomic 
profiles and regularly for the first critical 24 h and daily for a total of 
14 days for any lethality. It was observed that none of the animals died 
at a dose of 2000 mg/kg body weight. Hence, one hundredth (1/100th) 
cut-off dose (i.e. 20 mg/kg) was selected for the subsequent study.
Experimental procedure
Thirty albino rats were randomly divided into five groups and were 
treated for 12 days and observed for 21 days. All the groups received 
0.1 ml of CFA (10 mg/ml) in the left hind footpad except the negative 
control group of animals. Group 1, the negative control received only 
5 ml/kg 0.9%w/v saline solution orally. Group 2, the positive control 
group received no test drug and group 3 animals were administered with 
standard MTX at a dose of 0.075 mg/kg body weight. Similarly, group 4 
and group 5 rodents were administered with test drug Erdosteine at 
a dose of 10 mg/kg and 20 mg/kg body weight respectively. The time 
of adjuvant injection was referred to as day zero and treatment was 
initiated from day one and continued till the 12th day. The body weight 
and left hind paw volume of the animals were recorded consecutively 
on the 1st, 5th, 10th, 15th, and 20th day of experimentation [18,19]. The 
percentage inhibition of left paw edema was calculated by the following 
formula:
  % Inhibition = (VC–VT) × 100/VC (i) [20]
Where, VC = Paw volume of control group, VT = Paw edema volume of 
the test/standard group.
On the 19th day of experimentation, all the affected paws of the animals 
were photo radiographed to observe the soft tissue swelling and the 
bone space. On the 20thday of experimentation, the blood was collected 
from each group for hematological investigation and half of the 
population from each group were sacrificed, left leg was amputated at 
knee joints and were sent for histopathological evaluation [18,19].
The tissue samples of the tibiotarsal bone were stored in 10% Neutral 
Buffered Formalin. The bones were then decalcified by keeping in 5% 
Formic acid for 4–5 days. The histopathological tissue sections were 
sliced, stained with Hematoxylin–Eosin stain, and fixed on the slides 
and they were observed under a fluorescence microscope (OLYMPUS 
CX 21i TR) attached to a camera (OLYMPUS LC 30) [18].
RESULTS
Body weight
The graph Fig. 3 shows a quantitative change in the body weight of 
animals in each group. After induction of CFA there was a drastic decline 
Fig. 2: Erdosteine- metabolite 1
Fig. 1: Chemical structure of erdosteine
Fig. 3: Change in the body weight. Significant change in the body 
weight of Methotrexate and Erdosteine treated group. n=6, values 
are expressed as mean±SEM, Tukey. Comparison of all parameters 
of the control group with standard and test group were done, 
Non-significant (p>0.05) and significant (p<0.05)
in the body weight on day 10, which elevated due to the administration 
of the drugs (standard and test drug). However, no significant difference 
was found in the body weight between the two test groups administered 
with 10 mg/kg and 20 mg/kg of test drug. However, a significant 
difference between standard and group 5 (test drug 20 mg/kg) was 
found (p<0.05).
Paw volume
Fig. 4 clearly indicates maximum swelling in the paw during 5–10 days 
post-administration of CFA. However, reduction in the paw volume was 
seen during days 10–20 which indicated decrease in the inflammation. 
There was a significant decrease in the hind paw volume of all the 
drug-treated groups compared to the positive control group. Furthermore, 
substantial design in paw volume was observe in test group 2 compared 
to the standard group and test group 1. Table 1 represents mean and 
percent inhibition of paw volume. Percent Inhibition of arthritis increased 
in the standard and in both the test groups. However, better outcome was 
observed in test group 2 (Fig. 5). Tukey’s comparison of the data shows 
significant difference between the groups.
Haematological and biochemical estimation
The hemoglobin and RBC levels decreased in the positive control group 
which indicates that the induced arthritic rats were anemic. However, 
when compared with the standard and test groups their levels were 
normal post-induction. WBC drastically multiplied in number in positive 
control group indicating elevated inflammation in the hind paws. 
However, in the standard and test group, WBC count become normal 
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Table 1: Average paw volume and %inhibition of paw volume of the adjuvant-induced arthritis in Wistar Albino rats
Groups Day 1 Day 5 Day 10 Day 15 Day 20
Negative control
Average 0.12±0.11 0.18±0.06 0.21±0.05 0.22±0.06 0.17±0.06
%Inhibition 0 0 0 0 0
Positive control
Average 0.33±0.05 0.64±0.1 1.01±0.04 0.88±0.06 0.85±0.12
%Inhibition 67 36 1 12 15
Standard group
Average 0.27±0.08 0.68±0.05 0.60±0.09 0.46±0.05 0.37±0.12
%Inhibition 73 32 40 54 63
Test group 1
Average 0.29±0.06 0.45±0.15 0.55±0.05 0.31±0.09 0.21±0.07
%Inhibition 71 55 45 69 79
Test group 2
Average 0.27±0.09 0.59±0.09 0.32±0.08 0.22±0.07 0.15±0.05
%Inhibition 73 41 68 78 85
on day 21. Serum albumin is also one that can act as an inflammatory 
marker. Previous studies showed that decrease in the albumin level 
may be correlated with alteration in the RA condition related to the 
augmented level of pro-inflammatory cytokines [21]. Lower levels of 
serum albumin correspond to higher levels of inflammatory activity, 
as the albumin accumulates in the inflamed joint. The ESR value of the 
inflamed paws of arthritis rats in the positive control group was very 
high compared to the groups being treated with MTX and Erdosteine 
(Table 2). Besides, there is a significant change in the RF in all the 
drug-treated groups and in positive control. It was observed that the 
untreated group had a high level of RF than the groups treated with 
MTX and Erdosteine. Eventually, the test group being treated with 
20 mg/kg Erdosteine shows better result than the standard and test 
group.
Radiographical evaluation
Radiographs were evaluated to study the clinical features of the 
adjuvant-induced arthritis in rats. The soft skin thickening and the 
bone erosion were looked for. Pathological changes were compared 
between the control and the treatment groups. X-ray of normal rats 
(Fig. 6a) shows no pathological features, however, that of non-treated 
arthritic rats (Fig. 6b) shows severe soft tissue swelling (arrow), severe 
joint swelling, and very narrow joint space. X-ray of arthritic rats 
treated with MTX (Fig. 6c) at a dose of 0.075 mg/kg showed moderate 
soft tissue edema (arrow), moderate joint swelling, and very narrow 
joint space. Consequential changes were seen in x-rays of Erdosteine 
treated arthritic rats at a dose of 10 mg/kg (Fig. 6d) manifesting soft-
tissue edema, mild joint swelling, and moderate narrow joint space and 
at a dose of 20 mg/kg (Fig. 6e)showing no soft tissue edema or joint 
swelling and improved narrow joint space.
From the clinical radiographic features, it was observe that there was 
an improved prognosis in the groups treated with MTX and Erdosteine 
compared to the untreated group. Besides, improved treatment 
outcomes were observed in a dose-dependent manner.
Histopathological evaluation
Different slides from different groups were observed on the computer 
screen at a magnification of 10× and 40× and the photomicrographs 
were snapshot.
Photomicrograph of a tissue section of a rat from the Negative 
Control group showed no sign of inflammation, bone destruction, or 
inflammatory cells (Fig. 7a). Section of the tissue from the rat paw of the 
positive control group i.e., non-treated arthritic group, showed massive 
numbers of inflammatory cells infiltration, pannus formation, bone 
destruction, and narrow synovial space (Fig. 7b). Similarly, paw section 
of standard group demonstrates reduced inflammation and improved 
synovial space. In addition, lesser macrophages and neutrophils 
infiltration were observed in standard treated group. However, pannus 
formation and bone destruction were evident in this section (Fig. 7c). 
Bone destruction and inflammatory cells infiltration were much lesser 
in this section in test treated group 2 compared to group 1. From the 
result, it is evident that Erdosteine at a dose of 20 mg/kg is potent 
enough to decrease inflammation in RA.
DISCUSSION
As the etiology behind RA prognosis is not well understood confirmed 
curative measures are not discovered till date [14]. Current treatments 
include non-steroidal anti-inflammatory drugs (NSAIDs), DMARDs, 
and biologics, but none are curative and there is a significant “non-
responder” rate [22]. NSAIDs and DMARDS are associated with adverse 
Fig. 4: Change in Paw volume. Reduction of the paw volume 
after drug treatment on the arthritis-induced Albino rats. n=6 
rats in each group, values are expressed as mean±SEM, Tukey. 
Comparison of all parameters of the control group with standard 
and test group, Non-significant (p>0.05), Significant (p<0.05)
Fig. 5: % inhibition of paw volume using one way ANOVA, n=6 rats 
in each group, values are expressed as mean±SEM
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Table 2: Change in haematological and biochemical evaluation




Standard group Test group 1  
(10 mg/kg)
Test group 2  
(20 mg/kg)
1. Haemoglobin (g/dL) 16.1±5.5 9.7±2.4 12.8±4.7 12.5±4.2 13.8±3.3
2. Total WBC count (mm3) 7.3×103±5.4 10.3×103±4.4 11.6×103±4.3 8.4×103±4.6 6.6×103±5.1
3. Neutrophils (mm3) 2.6×103±2.6 3.6×103±2.5 4.6×103±1.9 1.3×103±3,2 1.9×103±2.6
4. Lymphocytes (mm3) 6.8×103±3.4 6.1×103±5.6 5.6×103±4.0 3.7×103±4.7 4.1×103±4.6
5. Monocytes (mm3) 0.02×103±0.02 0.03×103±0.02 0.03×103±0.01 0.01×103±0.01 0.01×103±0.01
6. Eosinophils (mm3) 0.05×103±0.03 0.07×103±0.02 0.04×103±0.01 0.04×103±0.02 0.03×103±0.01
7. Basophils (mm3) 0.01×103 0.0×103 0.0×103 0.0×103 0.0×103
8. RBC (mm3) 7.76×106±2.1 5.80×106±1.6 6.1×106±2.5 6.50×106±3.2 7.40×106±2.6
9. ESR (mm/h) 19.3±1.6 40±5.5 26.16±3.2 28±4.1 23.16±2.3
10. RA factor (mIU/ml) 3.9±1.6 5.2±2.6 3.8±2.2 3.2±1.5 2.9±0.7
11. Albumin (g/dL) 3.8±1.8 3.2±0.9 3.6±0.5 3.7±1.2 3.8±1.4
n=6, values were expressed as mean±SEM, Tukey. Comparison of all parameters of control group with standard and test group, Non significant (p>0.05), *Significant 
(p<0.05). RA: Rheumatoid arthritis.
effects [9]. Because of this reason, many patients and practitioners are 
seeking alternative approaches for providing an effective cure for the 
treatment of disease and to overcome the serious drawbacks such as 
gastrointestinal bleeding and bone loss. Hence, there is an urgent need 
to find safer compounds for the management of RA [11].
Rat adjuvant arthritis is an experimental model of polyarthritis which 
has been widely used for preclinical testing of numerous anti-arthritic 
agents which are either under preclinical or clinical investigation 
or are currently used as therapeutics in this disease [10]. It has been 
experimentally proved that adjuvant-induced arthritis in rat mimics the 
pathological, immunological, and clinical significance of human RA [20].
There was a significant difference in the result between the control and 
treatment groups in this study. It was observed that the body weight 
of the animals being treated started to improve on Day 10 along the 
course of the treatment but no improvement was seen in the untreated 
group of rats. Patil et al. suggest that the decrease in body weight 
during inflammation is due to deficient absorption of nutrients through 
the intestine [23]. In this study, standard group treated with MTX and 
the group treated with Erdosteine 20 mg/kg had a significant change 
p˂0.05 proving the decrease in inflammation.
Fig. 6: Radiographical images of paws of the rats under study.  
(a) X-ray image of a rat without CFA induced, treated with saline; 
(b) X-ray figure of a rat induced with CFA treated with saline;  
(c) X-ray of rat induced with CFA and treated with methotrexate; 
(d) X-ray image of rat induced with CFA treated with 10 mg/kg 
Erdosteine; (e) X-ray of rat induced with CFA treated with  




Fig. 7: Sections of tibiotarsal tissue sample of the rats for 
histological evaluation at 10× and 40×. (a) Negative control 
group (b) Positive control group without treatment; Sections of 
tibiotarsal tissue sample of the rats for histological evaluation 
at 10× and 40×. (c) Standard group treated with 0.075 mg/kg 
Methotrexate; (d) Test group 1 treated with 10 mg/kg Erdosteine; 
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CONCLUSION
In this study, treatment with MTX and Erdosteine as standard and 
test drug, respectively, in the arthritis induced groups recede the 
inflammation significantly. Furthermore, Erdosteine given at a dose of 
20 mg/kg was more effective compared to the standard drug. The results, 
therefore, supports that the test drug, Erdosteine can be a potential 
anti-inflammatory and anti-oxidant lead for the treatment of RA.
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